Dopamine D2 and D3 Receptor Occupancy in Normal Humans Treated with the Antipsychotic Drug Aripiprazole (OPC 14597): A Study Using Positron Emission Tomography and [11C]Raclopride

@article{Yokoi2002DopamineDA,
  title={Dopamine D2 and D3 Receptor Occupancy in Normal Humans Treated with the Antipsychotic Drug Aripiprazole (OPC 14597): A Study Using Positron Emission Tomography and [11C]Raclopride},
  author={Fuji Yokoi and Gerhard Gr{\"u}nder and Kathleen Bizi{\`e}re and M. Stephane and Ahmet Semih Doğan and Robert F. Dannals and Hayden T. Ravert and Ajit Suri and Steven L. Bramer and Dean F. Wong},
  journal={Neuropsychopharmacology},
  year={2002},
  volume={27},
  pages={248-259}
}

Figures and Tables from this paper

Dose–Occupancy Study of Striatal and Extrastriatal Dopamine D2 Receptors by Aripiprazole in Schizophrenia with PET and [18F]Fallypride

Correlations of ratings of clinical improvement with regional occupancy suggest that aripiprazole, as do other antipsychotics, benefits positive symptoms of schizophrenia most directly through its modulation of striatal rather than cortical or other extrastriatal dopamine activity.

Striatal and extrastriatal dopamine D2 receptor occupancy by the partial agonist antipsychotic drug aripiprazole in the human brain: a positron emission tomography study with [11C]raclopride and [11C]FLB457

The data suggest partial agonism at dopamine D2 receptors is the most likely explanation for the minimal risk of extrapyramidal side effects in the treatment by aripiprazole.

Effects of Dopamine D2 Receptor Partial Agonist Antipsychotic Aripiprazole on Dopamine Synthesis in Human Brain Measured by PET with L-[β-11C]DOPA

A significant negative correlation was observed between baseline dopamine synthesis capacity and changes in dopamine synthesis Capacity by aripiprazole, indicating that this antipsychotic appears to stabilize dopamine synthesiscapacity.

Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia

D2RO at plasma steady state of 60 mg ITI-007, a dose that previously demonstrated antipsychotic efficacy in a controlled trial, was determined and likely contributes to the favorable safety and tolerability profile of lumateperone with reduced risk for movement disorders and hyperprolactinemia.

Determination of dopamine D2 receptor occupancy by lurasidone using positron emission tomography in healthy male subjects

In healthy volunteers, single doses of lurasidone 40–80 mg resulted in D2 receptor occupancy levels of >60 %, a level of receptor occupancy previously associated with clinical response for atypical antipsychotics.

In vivo quantification of striatal dopamine D2 receptor occupancy by JNJ-37822681 using [11C]raclopride and positron emission tomography

Oral administration of JNJ-37822681 resulted in dose-dependent dopamine D2 receptor occupancy, which can produce occupancy levels that are generally associated with clinical efficacy for registered antipsychotic drugs.

Striatal and Extrastriatal D2/D3-Receptor-Binding Properties of Ziprasidone: A Positron Emission Tomography Study With [18F]Fallypride and [11C]Raclopride (D2/D3-Receptor Occupancy of Ziprasidone)

D2/D3-receptor occupancy is rapidly attuning to the daily course of ziprasidone plasma levels, suggesting relatively high intraday variations of D2/ D3- receptor binding.

Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study.

Its dissociation from those receptors is very slow, such that in patients with serum aripiprazole concentrations in the range typical for clinical practice, D(2)/D(3) receptors must remain nearly saturated for as long as 1 week after the last dose.

Predicting Dopamine D2 Receptor Occupancy From Plasma Levels of Antipsychotic Drugs: A Systematic Review and Pooled Analysis

It is suggested that D2 occupancy of antipsychotics could be estimated with a high degree of accuracy using widely available plasma levels.

Positron Emission Tomography studies of the D 1 dopamine receptor in schizophrenia THESIS FOR DOCTORAL DEGREE ( Ph . D . ) By Per Stenkrona

The result of the study does not support the prediction that selective D1R antagonism have antipsychotic effect in schizophrenia and the results suggest that the choice of ROI delineation method is not an important condition for reliability, whereas thorough movement correction is of importance.
...

References

SHOWING 1-10 OF 54 REFERENCES

Occupancy of striatal D2-like dopamine receptors after treatment with the sigma ligand EMD 57445, a putative atypical antipsychotic

The results suggest that a possible antipsychotic activity of E MD 57445 in schizophrenia is not necessarily attributable to its affinity for sigma receptors, but could be simply due to the potent antidopaminergic effects of EMD 59983, its main metabolite.

Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs.

Clinical doses of all the currently used classes of antipsychotic drugs cause a substantial blockade of central D2-dopamine receptors in humans, and this effect appears to be selective for the antipsychotics.

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects.

This finding indicates that neuroleptic-induced extrapyramidal syndromes are related to the degree of central D2 occupancy induced in the basal ganglia of drug-treated schizophrenic patients and demonstrates that clozapine is also "atypical" with respect to the central D1 occupancy in patients.

Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.

Clozapine, at doses known to be effective in routine clinical settings, showed a D 2 occupancy clearly lower than that of typical antipsychotics, while risperidone and olanzapine at their usual clinical doses gave the same level of D2 occupancy as low-dose typical antippsychotics.

A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy.

The data suggest that transient D2 occupancy may be sufficient for its antipsychotic effect, and future studies controlling for nonpharmacological effects as well as activities on other receptors will be necessary to confirm this suggestion.

High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study.

The findings demonstrate that low doses of haloperidol induce D2 receptor occupancies that are in the putative therapeutic range, and should encourage clinicians to initiate treatment of psychotic episodes with low (2-4 mg hal operidol equivalent) doses of typical neuroleptics, particularly for first-episode patients.

Effects of endogenous dopamine on kinetics of [3H]N‐methylspiperone and [3H]raclopride binding in the rat brain

Kinetic studies revealed a marked resistance of N‐methylspiperone (NMSP) to competition with endogenous dopamine released by amphetamine, which suggests significant differences in competition by [3H]NMSP and [3h]RAC in PET neuroreceptor studies.
...